Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia

Advicenne, a company specializing in treatments for rare kidney diseases, has received marketing authorization and reimbursement approval for its product, Sibnayal®, in Saudi Arabia. Sibnayal®, a combination of potassium citrate and potassium bicarbonate, targets distal Renal Tubular Acidosis (dRTA). The approval is based on the European registration dossier, and Saudi authorities have agreed to reimbursement rates aligned with top European pricing.

This development is the result of collaboration with Taïba Healthcare, a pharmaceutical distributor in the Gulf region. Advicenne holds the marketing authorization, while Taïba Healthcare oversees local marketing activities.

The prevalence of dRTA is notably higher in the Gulf, with an estimated 600 to 800 patients in Saudi Arabia. Sibnayal® is already accessible in other Gulf regions, and this success may facilitate further registrations in GCC countries.